Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis
Charles F
CF
Division of Hematology/Oncology, Comprehensive Cancer Center, and Center for Biostatistics, The Ohio State University, Columbus, Ohio 43210, USA.
Grainger
Andrew
A
Fischer
Beth
B
Baiocchi
Robert A
RA
Carrodeguas
Lester
L
Roychowdhury
Sameek
S
Chen
Lei
L
Banks
Amy L
AL
Davis
Thomas
T
Young
Donn
D
Kelbick
Nicole
N
Stephens
Julie
J
Byrd
John C
JC
Grever
Michael R
MR
Caligiuri
Michael A
MA
Porcu
Pierluigi
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage; D003131:Combined Modality Therapy / Q000379:methods*; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000378:metabolism; D007694:Killer Cells, Natural / Q000276:immunology; D007962:Leukocytes / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000628:therapy*; D008297:Male; D051379:Mice; D016513:Mice, SCID; D008875:Middle Aged; D000069283:Rituximab; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007376:Interleukin-2; D000069283:Rituximab